Pretreatment health-related quality of life profile according to the eortc QLQ-C30 in patients with myelodysplastic syndromes (MDS): Analysis on 443 lower-risk MDS patients in Blood
2018
ASL Asti
Tipo pubblicazione
Conference Abstract
Autori/Collaboratori (35)Vedi tutti...
Efficace F
Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy
Ricco A
Hematology - Dept. of Emergency and Organ Transplantation, University of Bari, Bari, Italy
Breccia M
Division of Cellular Biotechnologies and Hematology, University Sapienza, Roma, Italy
et alii...
Abstract
Background: Understanding health-related quality of life (HRQOL) profile, including functional aspects and symptom burden, of yet untreated patients with myelodysplastic syndromes (MDS) is important to help clinicians to better identify subgroup of patients in need of special attention from the very beginning of therapy. Aims: The primary objective of this study was to investigate baseline (i.e., pretreatment) HRQOL profile of untreated patients with lower-risk MDS, examining differences by age, gender, risk score category and comorbidity. A secondary objective was to provide age and sex baseline reference HRQOL values, according to the EORTC QLQ-C30 questionnaire, to be used as benchmark comparisons in future MDS studies. Methods: This analysis is based on 443 newly diagnosed adult MDS patients with International Prognostic Scoring System (IPSS) risk score of low (46 %) or intermediate-1 (54%), enrolled in an international prospective cohort observational study. Median age was 75 years (range 32-94), with 261 men (59%) and 182 (41%) women. HRQOL was assessed by the EORTC QLQ-C30 questionnaire at study entry, before any treatment (except for transfusions). This well validated questionnaire consists of five functioning scales: physical, role, emotional, cognitive and social; three symptom scales: fatigue, nausea/ vomiting and pain; six single item scales: dyspnoea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact; and the global health status/HRQOL scale. The items were scaled and scored using the recommended EORTC procedures. At the time of baseline HRQOL assessment, 111 (25%) patients had received at least one red blood cell transfusion. We used Wilcoxon-Mann-Whitney and Kruskal- Wallis tests for all comparisons. We used the false discovery rate approach to account for multiple testing, with a nominal ?-level=0.05. In addition to statistical significance, clinically relevant HRQOL differences were also evaluated based on previou
Se sei accreditato in BVS-P effettua l'accesso per utilizzare i nostri servizi.
DOI : 10.1182/blood-2018-99-110921
Keywords
cohort analysis; nausea and vomiting; male; myelodysplastic syndrome; cock (bird); aged; adult; loss of appetite; major clinical study; Kruskal Wallis test; International Prognostic Scoring System; insomnia; human; global health; gender; female; fatigue; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; erythrocyte transfusion; dyspnea; diarrhea; controlled study; constipation; conference abstract; comorbidity; statistical significance; risk assessment; reference value; quality of life; pain; prospective study; observational study;